General information about company |
|||
|---|---|---|---|
| Scrip Code | 544293 | ||
| NSE Symbol | SURAKSHA | ||
| MSEI Symbol | NOTLISTED | ||
| ISIN | INE877V01027 | ||
| Name of company | SURAKSHA DIAGNOSTIC LIMITED | ||
| Type of company | Main Board | ||
| Class of security | Equity | ||
| Date of start of financial year | 01-Apr-2024 | ||
| Date of end of financial year | 31-Mar-2025 | ||
| Date of board meeting when results were approved | 28-May-2025 | ||
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 21-May-2025 | ||
| Description of presentation currency | INR (in Actuals) | ||
| Reporting Type | Quarterly | ||
| Reporting Quarter | Fourth quarter | ||
| Nature of report standalone or consolidated | Standalone | ||
| Whether results are audited or unaudited for the quarter ended | Audited | ||
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | Audited | ||
| Segment Reporting | Single segment | ||
| Description of single segment | DIAGNOSTIC | ||
| Start date and time of board meeting | 28-May-2025 14:00:00 | ||
| End date and time of board meeting | 28-May-2025 18:30:00 | ||
| Whether cash flow statement is applicable on company | Yes | ||
| Type of cash flow statement | Cash Flow Indirect | ||
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion | ||
| Whether the company has any related party? | Yes | ||
| Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? | Yes | ||
| (I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public | NA | ||
| (II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. | NA | ||
| Whether the company is a high value debt listed entity according to regulation 15 (1A)? | No | ||
| (a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication? | |||
| (b) If answer to above question is No, please explain the reason for not complying. | |||
| Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? | Yes | ||
| Latest Date on which RPT policy is updated | 2025-02-08 | ||
| Indicate Company website link for updated RPT policy of the Company | https://www.surakshanet.com/pdf/investor/Related%20Party%20Transaction%20Policy10-02-2025.pdf | ||
| Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? | No | ||
| No. of times funds raised during the quarter | |||
| Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? | No | ||
| No default | |||
Financial Results Ind-AS |
|||
|---|---|---|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
| A | Date of start of reporting period | 01-Jan-2025 | 01-Apr-2024 |
| B | Date of end of reporting period | 31-Mar-2025 | 31-Mar-2025 |
| C | Whether results are audited or unaudited | Audited | Audited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Part I | Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column. | ||
| 1 | Income | ||
| Revenue from operations | 641451000 | 2490954000 | |
| Other income | 9421000 | 43830000 | |
| Total income | 650872000 | 2534784000 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 85889000 | 289454000 |
| (b) | Purchases of stock-in-trade | 0 | 0 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | 0 | 0 |
| (d) | Employee benefit expense | 99952000 | 419058000 |
| (e) | Finance costs | 20633000 | 83853000 |
| (f) | Depreciation, depletion and amortisation expense | 86593000 | 347283000 |
| (f) | Other Expenses | ||
| 1 | Impairment loss | 8023000 | 21858000 |
| 2 | Advertisement | 11956000 | 37541000 |
| 3 | Rent Expenses | 13681000 | 35502000 |
| 4 | Power and fuel | 11105000 | 72688000 |
| 5 | Professional fees paid | 107896000 | 412708000 |
| 6 | Repairs and maintenance | 23442000 | 81927000 |
| 7 | Information technology expenses | 15569000 | 53181000 |
| 8 | Security and housekeeping charges | 15117000 | 55597000 |
| 9 | Commission to collection centre | 6242000 | 34896000 |
| 10 | Other Expenses | 44368000 | 150641000 |
| Total other expenses | 257399000 | 956539000 | |
| Total expenses | 550466000 | 2096187000 | |
| 3 | Total profit before exceptional items and tax | 100406000 | 438597000 |
| 4 | Exceptional items | 0 | 0 |
| 5 | Total profit before tax | 100406000 | 438597000 |
| 6 | Tax expense | ||
| 7 | Current tax | 14631000 | 102861000 |
| 8 | Deferred tax | 5708000 | 1336000 |
| 9 | Total tax expenses | 20339000 | 104197000 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0 | 0 |
| 11 | Net Profit Loss for the period from continuing operations | 80067000 | 334400000 |
| 12 | Profit (loss) from discontinued operations before tax | 0 | 0 |
| 13 | Tax expense of discontinued operations | 0 | 0 |
| 14 | Net profit (loss) from discontinued operation after tax | 0 | 0 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0 | 0 |
| 16 | Total profit (loss) for period | 80067000 | 334400000 |
| 17 | Other comprehensive income net of taxes | -634000 | -2039000 |
| 18 | Total Comprehensive Income for the period | 79433000 | 332361000 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | |||
| Total profit or loss, attributable to non-controlling interests | |||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 104162000 | 104162000 | |
| Face value of equity share capital | 2 | 2 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | 0 | |
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 1.54 | 6.42 | |
| Diluted earnings (loss) per share from continuing operations | 1.54 | 6.42 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 1.54 | 6.42 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 1.54 | 6.42 | |
| 24 | Debt equity ratio | 0 | 0 |
| 25 | Debt service coverage ratio | 0 | 0 |
| 26 | Interest service coverage ratio | 0 | 0 |
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
Disclosure of notes on financial results |
|||
|---|---|---|---|
| Textual Information(1) | 1. The standalone financial results for the quarter and financial year ended 31 March 2025 of Suraksha Diagnostic Limited have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard Ind AS notified under Section 133 of the Companies Act 2013 as amended read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI Listing Regulations 2015 as amended. n2. These financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on 28 May 2025. These financial results for the year ended 31 March 2025 have been audited by the statutory auditor and they have issued an unmodified opinion. n3. The standalone figures for the quarter ended 31 March 2025 are the balancing figures between the audited standalone figures in respect of the full financial year and the published unaudited year to date standalone figures up to the third quarter of the financial year. n4. The figures for the quarter ended 31 March 2024 are presented based on the information complied by the management in accordance with Ind AS and have not been subject to review or audit by the statutory auditors or by any other auditor. However the management has prepared the results for the said period by applying consistent accounting policies. n5. During the year ended 31 March 2025 0.0001 percentage Compulsorily Convertible Preference Shares aggregating to 162859 preference shares of par value Rs 100 each were converted into 8955761 equity shares of par value of Rs 2 each. n6. During the year ended 31 March 2025 the Company has completed an Initial Public Offering entirely as offer for sale of 19189330 equity shares by existing share holders with face value of Rs.2 and listed on both National Stock exchange and Bombay Stock Exchange on December 06 2024. n7. During the year ended 31 March 2025 the Nomination and Remuneration Committee had approved grant of 208164 stock options to employees under the Suraksha Employee Stock Option Scheme 2024. The Company has accounted for these stock options in accordance with Ind AS 102 Share Based Payments. n8. The Company is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 Operating Segments. n9. During the quarter ended 31 March 2025 the Company had entered into a Share Subscription Agreement for subscribing to 95841 equity shares of Rs 10 each representing 16.17 percent of the total equity share capital of Fetomat Wellness Private Limited. Subsequent to financial year ended 31 March 2025 the Company had entered into Share Purchase Agreements with existing shareholders of Fetomat for acquisition of 277582 equity shares of Rs 10 each representing 46.83 percent of the total equity share capital of Fetomat resulting in Fetomat becoming a subsidiary of the Company. n10. These financial results are also available on the Companys website at www.surakshanet.com and on the stock exchange websites at www.bseindia.com and www.nseinda.com. n11. Previous periods or years figures have been regrouped or reclassified wherever necessary to conform to current periods or years classification. | ||
Remarks |
|
|---|---|
| Debt equity ratio | |
| Debt service coverage ratio | |
| Interest service coverage ratio | |
Statement of Asset and Liabilities |
|||
|---|---|---|---|
| Particulars | Year ended (dd-mm-yyyy) | ||
| Date of start of reporting period | 01-Apr-2024 | ||
| Date of end of reporting period | 31-Mar-2025 | ||
| Whether results are audited or unaudited | Audited | ||
| Nature of report standalone or consolidated | Standalone | ||
| Assets | |||
| 1 | Non-current assets | ||
| Property, plant and equipment | 1393829000 | ||
| Capital work-in-progress | 53203000 | ||
| Investment property | 0 | ||
| Goodwill | 0 | ||
| Other intangible assets | 757701000 | ||
| Intangible assets under development | 4934000 | ||
| Biological assets other than bearer plants | 0 | ||
| Investments accounted for using equity method | 0 | ||
| Non-current financial assets | |||
| Non-current investments | 27148000 | ||
| Trade receivables, non-current | 0 | ||
| Loans, non-current | 138723000 | ||
| Other non-current financial assets | 426367000 | ||
| Total non-current financial assets | 592238000 | ||
| Deferred tax assets (net) | 0 | ||
| Other non-current assets | 86392000 | ||
| Total non-current assets | 2888297000 | ||
| 2 | Current assets | ||
| Inventories | 80165000 | ||
| Current financial asset | |||
| Current investments | 0 | ||
| Trade receivables, current | 150580000 | ||
| Cash and cash equivalents | 14754000 | ||
| Bank balance other than cash and cash equivalents | 140531000 | ||
| Loans, current | 0 | ||
| Other current financial assets | 25217000 | ||
| Total current financial assets | 331082000 | ||
| Current tax assets (net) | 0 | ||
| Other current assets | 31459000 | ||
| Total current assets | 442706000 | ||
| 3 | Non-current assets classified as held for sale | 0 | |
| 4 | Regulatory deferral account debit balances and related deferred tax Assets | 0 | |
| Total assets | 3331003000 | ||
| Equity and liabilities | |||
| 1 | Equity | ||
| Equity attributable to owners of parent | |||
| Equity share capital | 104162000 | ||
| Other equity | 2038960000 | ||
| Total equity attributable to owners of parent | 2143122000 | ||
| Non controlling interest | |||
| Total equity | 2143122000 | ||
| 2 | Liabilities | ||
| Non-current liabilities | |||
| Non-current financial liabilities | |||
| Borrowings, non-current | 28754000 | ||
| Trade payables, non-current | |||
| (A) Total outstanding dues of micro enterprises and small enterprises | 0 | ||
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 0 | ||
| Total Trade payable | 0 | ||
| Other non-current financial liabilities | 712281000 | ||
| Total non-current financial liabilities | 741035000 | ||
| Provisions, non-current | 10222000 | ||
| Deferred tax liabilities (net) | 54509000 | ||
| Deferred government grants, Non-current | 0 | ||
| Other non-current liabilities | 0 | ||
| Total non-current liabilities | 805766000 | ||
| Current liabilities | |||
| Current financial liabilities | |||
| Borrowings, current | 29498000 | ||
| Trade payables, current | |||
| (A) Total outstanding dues of micro enterprises and small enterprises | 19674000 | ||
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 120211000 | ||
| Total Trade payable | 139885000 | ||
| Other current financial liabilities | 189701000 | ||
| Total current financial liabilities | 359084000 | ||
| Other current liabilities | 21779000 | ||
| Provisions, current | 1252000 | ||
| Current tax liabilities (Net) | 0 | ||
| Deferred government grants, Current | 0 | ||
| Total current liabilities | 382115000 | ||
| 3 | Liabilities directly associated with assets in disposal group classified as held for sale | 0 | |
| 4 | Regulatory deferral account credit balances and related deferred tax liability | 0 | |
| Total liabilities | 1187881000 | ||
| Total equity and liabilites | 3331003000 | ||
| Disclosure of notes on assets and liabilities | |||
Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results |
|||||||
|---|---|---|---|---|---|---|---|
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
| Date of start of reporting period | 01-Jan-2025 | 01-Apr-2024 | |||||
| Date of end of reporting period | 31-Mar-2025 | 31-Mar-2025 | |||||
| Whether accounts are audited or unaudited | Audited | Audited | |||||
| Nature of report standalone or consolidated | Standalone | Standalone | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
Other Comprehensive Income |
|||
|---|---|---|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
| A | Date of start of reporting period | 01-Jan-2025 | 01-Apr-2024 |
| B | Date of end of reporting period | 31-Mar-2025 | 31-Mar-2025 |
| C | Whether results are audited or unaudited | Audited | Audited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Remeasurement gain/(loss) of net defined benefit plan | -847000 | -2725000 |
| 2 | Income tax effect on above | 213000 | 686000 |
| Total Amount of items that will not be reclassified to profit and loss | -634000 | -2039000 | |
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 0 | 0 |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0 | 0 |
| 5 | Total Other comprehensive income | -634000 | -2039000 |
Cash flow statement, indirect |
||||||
|---|---|---|---|---|---|---|
| Particulars | Year ended (dd-mm-yyyy) | |||||
| A | Date of start of reporting period | 01-Apr-2024 | ||||
| B | Date of end of reporting period | 31-Mar-2025 | ||||
| C | Whether results are audited or unaudited | Audited | ||||
| D | Nature of report standalone or consolidated | Standalone | ||||
| Part I | Blue color marked fields are non-mandatory. | |||||
| Statement of cash flows | ||||||
| Cash flows from used in operating activities | ||||||
| Profit before tax | 438597000 | |||||
| Adjustments for reconcile profit (loss) | ||||||
| Adjustments for finance costs | 83853000 | |||||
| Adjustments for decrease (increase) in inventories | -13634000 | |||||
| Adjustments for decrease (increase) in trade receivables, current | -81808000 | |||||
| Adjustments for decrease (increase) in trade receivables, non-current | 0 | |||||
| Adjustments for decrease (increase) in other current assets | -9981000 | |||||
| Adjustments for decrease (increase) in other non-current assets | 0 | |||||
| Adjustments for other financial assets, non-current | -30854000 | |||||
| Adjustments for other financial assets, current | 0 | |||||
| Adjustments for other bank balances | 0 | |||||
| Adjustments for increase (decrease) in trade payables, current | -773000 | |||||
| Adjustments for increase (decrease) in trade payables, non-current | 0 | |||||
| Adjustments for increase (decrease) in other current liabilities | 4792000 | |||||
| Adjustments for increase (decrease) in other non-current liabilities | 0 | |||||
| Adjustments for depreciation and amortisation expense | 347282000 | |||||
| Adjustments for impairment loss reversal of impairment loss recognised in profit or loss | 21858000 | |||||
| Adjustments for provisions, current | 1036000 | |||||
| Adjustments for provisions, non-current | 0 | |||||
| Adjustments for other financial liabilities, current | 9095000 | |||||
| Adjustments for other financial liabilities, non-current | 0 | |||||
| Adjustments for unrealised foreign exchange losses gains | 0 | |||||
| Adjustments for dividend income | 0 | |||||
| Adjustments for interest income | 38077000 | |||||
| Adjustments for share-based payments | 0 | |||||
| Adjustments for fair value losses (gains) | 0 | |||||
| Adjustments for undistributed profits of associates | 0 | |||||
| Other adjustments for which cash effects are investing or financing cash flow | 0 | |||||
| Other adjustments to reconcile profit (loss) | 0 | |||||
| Other adjustments for non-cash items | 2358000 | |||||
| Share of profit and loss from partnership firm or association of persons or limited liability partnerships | 0 | |||||
| Total adjustments for reconcile profit (loss) | 295147000 | |||||
| Net cash flows from (used in) operations | 733744000 | |||||
| Dividends received | 0 | |||||
| Interest paid | 0 | |||||
| Interest received | 0 | |||||
| Income taxes paid (refund) | 105764000 | |||||
| Other inflows (outflows) of cash | 0 | |||||
| Net cash flows from (used in) operating activities | 627980000 | |||||
| Cash flows from used in investing activities | ||||||
| Cash flows from losing control of subsidiaries or other businesses | 0 | |||||
| Cash flows used in obtaining control of subsidiaries or other businesses | 15574000 | |||||
| Other cash receipts from sales of equity or debt instruments of other entities | 0 | |||||
| Other cash payments to acquire equity or debt instruments of other entities | 74832000 | |||||
| Other cash receipts from sales of interests in joint ventures | 0 | |||||
| Other cash payments to acquire interests in joint ventures | 0 | |||||
| Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships | 0 | |||||
| Cash payment for investment in partnership firm or association of persons or limited liability partnerships | 0 | |||||
| Proceeds from sales of property, plant and equipment | 1495000 | |||||
| Purchase of property, plant and equipment | 353885000 | |||||
| Proceeds from sales of investment property | 0 | |||||
| Purchase of investment property | 0 | |||||
| Proceeds from sales of intangible assets | 0 | |||||
| Purchase of intangible assets | 0 | |||||
| Proceeds from sales of intangible assets under development | 0 | |||||
| Purchase of intangible assets under development | 0 | |||||
| Proceeds from sales of goodwill | 0 | |||||
| Purchase of goodwill | 0 | |||||
| Proceeds from biological assets other than bearer plants | 0 | |||||
| Purchase of biological assets other than bearer plants | 0 | |||||
| Proceeds from government grants | 0 | |||||
| Proceeds from sales of other long-term assets | 0 | |||||
| Purchase of other long-term assets | 0 | |||||
| Cash advances and loans made to other parties | 0 | |||||
| Cash receipts from repayment of advances and loans made to other parties | 0 | |||||
| Cash payments for future contracts, forward contracts, option contracts and swap contracts | 0 | |||||
| Cash receipts from future contracts, forward contracts, option contracts and swap contracts | 0 | |||||
| Dividends received | 0 | |||||
| Interest received | 32540000 | |||||
| Income taxes paid (refund) | 0 | |||||
| Other inflows (outflows) of cash | 17416000 | |||||
| Net cash flows from (used in) investing activities | -392840000 | |||||
| Cash flows from used in financing activities | ||||||
| Proceeds from changes in ownership interests in subsidiaries | 0 | |||||
| Payments from changes in ownership interests in subsidiaries | 0 | |||||
| Proceeds from issuing shares | 0 | |||||
| Proceeds from issuing other equity instruments | 0 | |||||
| Payments to acquire or redeem entity's shares | 0 | |||||
| Payments of other equity instruments | 0 | |||||
| Proceeds from exercise of stock options | 0 | |||||
| Proceeds from issuing debentures notes bonds etc | 0 | |||||
| Proceeds from borrowings | 28114000 | |||||
| Repayments of borrowings | 0 | |||||
| Payments of lease liabilities | -206999000 | |||||
| Dividends paid | 0 | |||||
| Interest paid | -6367000 | |||||
| Income taxes paid (refund) | 0 | |||||
| Other inflows (outflows) of cash | 0 | |||||
| Net cash flows from (used in) financing activities | 241480000 | |||||
| Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes | 476620000 | |||||
| Effect of exchange rate changes on cash and cash equivalents | ||||||
| Effect of exchange rate changes on cash and cash equivalents | 0 | |||||
| Net increase (decrease) in cash and cash equivalents | 476620000 | |||||
| Cash and cash equivalents cash flow statement at beginning of period | 21094000 | |||||
| Cash and cash equivalents cash flow statement at end of period | 497714000 | |||||
Details of Impact of Audit Qualification |
|
|---|---|
| Whether results are audited or unaudited | Audited |
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Auditor's opinion | |
| Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results | Yes |
| Sr No. | Audit firm's name | Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI | Certificate valid upto | ||
| 1 | MSKA & Associates | Yes | 31-Jul-2027 | ||
|---|---|---|---|---|---|
Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter) |
| Sr No. | Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. | ||||||||||||||||||||||||
| Details of the party (listed entity/subsidiary) entering into the transaction | Details of the counterparty | Type of related party transaction | Details of other related party transaction | Value of the related party transaction as approved by the audit committee | Remarks on approval by audit committee | Value of the related party transaction ratified by the audit committee | Date of Audit Committee Meeting where the ratification was approved | Value of transaction during the reporting period | In case monies are due to either party as a result of the transaction | In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments | Details of the loans, inter-corporate deposits, advances or investments | Notes | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | PAN | Name | PAN | Relationship of the counterparty with the listed entity or its subsidiary | Opening balance | Closing balance | Nature of indebtedness (loan/ issuance of debt/ any other etc.) | Details of other indebtedness | Cost | Tenure | Nature (loan/ advance/ intercorporate deposit/ investment ) | Interest Rate (%) | Tenure | Secured/ unsecured | Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage) | ||||||||||
| 1 | Suraksha Diagnostic Limited | Suraksha Diagnostic & Eye Centre Private Limited | Enterprises owned or significantly influenced by KMP | Sale of goods or services | 45000000 | NA | 16210000 | 10520000 | 14956000 | ||||||||||||||||
| 2 | Suraksha Diagnostic Limited | Asian Institute of Immunology and Rheumatology LLP | Subsidiary of the Company | Sale of goods or services | 30000000 | NA | 9970000 | 1265000 | 8932000 | ||||||||||||||||
| 3 | Suraksha Diagnostic Limited | Suraksha Salvia LLP | Subsidiary of the Company | Sale of goods or services | 10000000 | NA | 568000 | 4773000 | 5244000 | ||||||||||||||||
| 4 | Suraksha Diagnostic Limited | Sahayta Clinic LLP | Enterprises owned or significantly influenced by KMP | Sale of goods or services | 300000 | Ratified | 220000 | 0 | 4000 | ||||||||||||||||
| 5 | Suraksha Diagnostic Limited | R.A. Enterprises | Enterprises owned or significantly influenced by KMP | Purchase of goods or services | 150000000 | NA | 65401000 | 12193000 | 14804000 | ||||||||||||||||
| 6 | Suraksha Diagnostic Limited | Kejriwal Electronics Limited | Enterprises owned or significantly influenced by KMP | Purchase of goods or services | 50000000 | NA | 62000 | 0 | 0 | ||||||||||||||||
| 7 | Suraksha Diagnostic Limited | Oscar Enclave Private Limited | Enterprises owned or significantly influenced by KMP | Any other transaction | Rent Expenses | 23045000 | NA | 23045000 | 3515000 | 3515000 | |||||||||||||||
| 8 | Suraksha Diagnostic Limited | Kejriwal Constructions | Enterprises owned or significantly influenced by KMP | Any other transaction | Rent Expenses | 3110000 | NA | 3110000 | 474000 | 474000 | |||||||||||||||
| 9 | Suraksha Diagnostic Limited | Suresh Enterprise | Enterprises owned or significantly influenced by KMP | Any other transaction | Rent Expenses | 1713000 | NA | 1713000 | 261000 | 261000 | |||||||||||||||
| 10 | Suraksha Diagnostic Limited | Raghavi Mittal | Relative of KMP | Remuneration | 1500000 | NA | 450000 | 64000 | 64000 | ||||||||||||||||
| 11 | Suraksha Diagnostic Limited | Aparajita Chatterjee | Relative of KMP | Any other transaction | Professional fee | 3000000 | NA | 1151000 | 172000 | 176000 | |||||||||||||||
| 12 | Suraksha Diagnostic Limited | Tandra Chatterjee | Relative of KMP | Any other transaction | Professional fee | 300000 | NA | 34000 | 9000 | 7000 | |||||||||||||||
| 13 | Suraksha Diagnostic Limited | Sahayta Clinic LLP | Enterprises owned or significantly influenced by KMP | Any other transaction | Commission paid | 300000 | NA | 53000 | 46000 | 28000 | |||||||||||||||
| 14 | Suraksha Diagnostic Limited | Suraksha Speciality LLP | Subsidiary of the Company | Interest received | 0 | NA | 585000 | 0 | 0 | ||||||||||||||||
| 15 | Suraksha Diagnostic Limited | Asian Institute of Immunology and Rheumatology LLP | Subsidiary of the Company | Interest received | 0 | NA | 414000 | 0 | 0 | ||||||||||||||||
| 16 | Suraksha Diagnostic Limited | Suraksha Radiology Private Limited | Subsidiary of the Company | Interest received | 0 | NA | 4029000 | 0 | 0 | ||||||||||||||||
| 17 | Suraksha Diagnostic Limited | Asian Institute of Immunology and Rheumatology LLP | Subsidiary of the Company | Loan | 0 | NA | -2000000 | 11244000 | 9172000 | Loan | 0.08 | 5year | Unsecured | Working capital requirement | |||||||||||
| 18 | Suraksha Diagnostic Limited | Suraksha Radiology Private Limited | Subsidiary of the Company | Loan | 0 | NA | 3000000 | 103210000 | 109857000 | Loan | 0.08 | 4year | Unsecured | Purchase of medical equipment | |||||||||||
| 19 | Suraksha Diagnostic Limited | Suraksha Speciality LLP | Subsidiary of the Company | Loan | 0 | NA | 1200000 | 17965000 | 19692000 | Loan | 0.07 | 5year | Unsecured | Working capital requirement | |||||||||||
| 20 | Suraksha Diagnostic Limited | Suraksha Speciality LLP | Subsidiary of the Company | Advance | 0 | NA | 59000 | 158000 | 217000 | ||||||||||||||||
| 21 | Suraksha Diagnostic Limited | Asian Institute of Immunology and Rheumatology LLP | Subsidiary of the Company | Advance | 0 | NA | -732000 | 737000 | 6000 | ||||||||||||||||
| 22 | Suraksha Diagnostic Limited | Suraksha Radiology Private Limited | Subsidiary of the Company | Advance | 0 | NA | 668000 | 914000 | 1582000 | ||||||||||||||||
| 23 | Suraksha Diagnostic Limited | Suraksha Salvia LLP | Subsidiary of the Company | Advance | 0 | NA | 401000 | 3136000 | 3537000 | ||||||||||||||||
| 24 | Suraksha Diagnostic Limited | Ritu Mittal | Key Managerial Personnel | Remuneration | 0 | NA | 10800000 | 1118000 | 1118000 | ||||||||||||||||
| 25 | Suraksha Diagnostic Limited | Somnath Chatterjee | Key Managerial Personnel | Remuneration | 0 | NA | 10800000 | 1118000 | 1118000 | ||||||||||||||||
| 26 | Suraksha Diagnostic Limited | Asian Institute of Immunology and Rheumatology LLP | Subsidiary of the Company | Investment | 0 | NA | 0 | 12000000 | 12000000 | ||||||||||||||||
| 27 | Suraksha Diagnostic Limited | Suraksha Speciality LLP | Subsidiary of the Company | Investment | 0 | NA | 0 | 5000000 | 5000000 | ||||||||||||||||
| 28 | Suraksha Diagnostic Limited | Suraksha Radiology Private Limited | Subsidiary of the Company | Investment | 0 | NA | 0 | 74000 | 74000 | ||||||||||||||||
| 29 | Suraksha Diagnostic Limited | Oscar Enclave Private Limited | Enterprises owned or significantly influenced by KMP | Any other transaction | Security deposit given | 0 | NA | 0 | 11460000 | 11460000 | |||||||||||||||
| 30 | Suraksha Diagnostic Limited | Suresh Enterprise | Enterprises owned or significantly influenced by KMP | Any other transaction | Security deposit given | 0 | NA | 0 | 1200000 | 1200000 | |||||||||||||||
| 31 | Suraksha Diagnostic Limited | Suraksha Advance Radiology Private Limited | Subsidiary of the Company | Advance | 0 | NA | 0 | 0 | 0 | ||||||||||||||||
| 32 | Suraksha Diagnostic Limited | Suraksha Advance Radiology Private Limited | Subsidiary of the Company | Investment | 0 | NA | 74000 | 0 | 74000 | ||||||||||||||||
| Total value of transaction during the reporting period | 151285000 | ||||||||||||||||||||||||